CA2469048A1 - Quinolinones as prostaglandin receptor ligands - Google Patents

Quinolinones as prostaglandin receptor ligands Download PDF

Info

Publication number
CA2469048A1
CA2469048A1 CA002469048A CA2469048A CA2469048A1 CA 2469048 A1 CA2469048 A1 CA 2469048A1 CA 002469048 A CA002469048 A CA 002469048A CA 2469048 A CA2469048 A CA 2469048A CA 2469048 A1 CA2469048 A1 CA 2469048A1
Authority
CA
Canada
Prior art keywords
6alkyl
halo
optionally substituted
group
6alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002469048A
Other languages
French (fr)
Inventor
Daniel Dube
Denis Deschenes
Rejean Fortin
Yves Girard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2469048A1 publication Critical patent/CA2469048A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Abstract

This invention encompasses a method for treating a prostaglandin E mediated disease or condition comprising administering to a mammalian patient in need of such treatment a compound of Formula (A) in an amount that is effective to treat the prostaglandin E mediated disease or condition.

Description

TITLE OF THE INVENTION
QUINOLINONES AS PROSTAGLANDIN RECEPTOR LIGANDS
BACKGROUND OF THE INVENTION
This invention relates to compounds and methods for treating prostaglandin E mediated diseases, and certain pharmaceutical compositions thereof.
More ,particularly, the compounds of the invention are structurally different from NSAIDs and opiates, and are antagonists of the pain and inflammatory effects of E-type prostaglandins.
Two review articles describe the characterization and therapeutic relevance of the prostanoid receptors as well as the most commonly used selective agonists and antagonists: Eicosazzoids: Frozn Bioteclzzzology to Therapeutic Applicatiozzs, Folco, Samuelsson, Maclouf, and Velo eds, Plenum Press, New York, 1996, chap. 14, 137-154 and Journal of Lipid Mediators and Cell Signalling, 1996, 14, 83-87. An article from The BYitislz Jounzal of Phazsyzacology (1994, 112, 740) suggests that Prostaglandin E2 (PGE2) exerts allodynia through the EP1 receptor subtype and hyperalgesia through EP2 and EP3 receptors in the mouse spinal cord.
Thus, selective prostaglandin ligands, agonists or antagonists, depending on which prostaglandin E receptor subtype is being considered, have anti-inflammatory, antipyretic and analgesic properties similar to a conventional non-steroidal anti-inflammatory drug, and in addition, inhibit hormone-induced uterine contractions and have anti-cancer effects. These compounds have a diminished ability to induce some of the mechanism-based side effects of NSAIDs which are indiscriminate cyclooxygenase inhibitors. In particular, the compounds have a reduced potential for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced effect on 'bleeding times and a lessened ability to induce asthma attacks in aspirin-sensitive asthmatic subjects.
In The American Physiological Society (1994, 267, 8289-R-294), studies suggest that PGE2-induced hyperthermia in the rat is mediated predominantly through the EP1 receptor. World patent applications WO 96/06822 (March 7, 1996), 2 (April 25, 1996) and EP 752421-A1 (January 08, 1997) disclose compounds as being useful in the treatment of prostaglandin mediated diseases.

This invention encompasses a method for treating a prostaglandin E
mediated disease or condition comprising administering to a mammalian patient in need of such treatment a compound of Formula A:
Ri R6 ~ ~ , R2 R5iyN.

A
in an amount that is effective to treat the prostaglandin E mediated disease or condition.
DETAILED DESCRIPTION OF THE INVENTION
This invention encompasses a method for treating a prostaglandin E
mediated disease or condition comprising administering to a mammalian patient in need of such treatment a compound of Formula A:
R~ R1 Rs \ \ R2 R5 ~ N~O
Ra Rs A
or a pharmaceutically acceptable salt, hydrate, ester or tautomer thereof, wherein:
R1 is selected from the group consisting of:
(1) hydrogen, (2) halo, (3) hydroxy, (4) C1_6alkyl, (5) C1_6allcenyl, (6) Cl_6alkoxy, (7) C1-6alkyl-S(O)m-, wherein m is 0, 1, 2 or 3 (8) C1_6allcyl-C(O)-(7) Cl_6allcoxy-C(O)-(9) Cl_6alkyl-C(O)-O-( 10) aryl, ( 11 ) arallcyl, (12) aryloxy, (13) aralkoxy, (14) arylthio, (15) amyl, (16) aroyloxy, and (17) N(RS)2, wherein the allcyl , alkenyl and aryl portions of items (4)-(16) above are optionally substituted from one up to the maximum number of substituable positions with a member independently selected from the group consisting of: halo, heterocycle, Cl_ 6alkoxy, C1_6alkyl-S(O)k-, wherein k is 0, 1 or 2, C1_6alkyl-C(O)-, Cl_6alkoxy-C(O), C1_6allcyl-C(O)-O, carboxy, hydroxy and aralkoxy, the alkyl portions of said Cl_6allcoxy, Cl_6alkyl-S(O)k-, Cl_6alkyl-C(O)-, C1_6alkoxy-C(O) and Cl_6alkyl-C(O)-O groups optionally substituted with 1-3 substituents independently selected from: halo and hydroxy, said aryl portions of items (10)-(16) above further optionally substituted from one up to the maximum number of substituable positions with C1_6alkyl, optionally substituted with 1-3 substituents independently selected from the group consisting of:
halo and hydroxy;
R2 is selected from the group consisting of:
(1) benzyl, optionally substituted with 1-3 substituents independently selected from the group consisting of:
(a) halo, (b) aryl, (c) aryloxy, (d) aryl-S(O)h-, wherein lc is 0, 1 or 2, (e) heterocycle, (f) arallcyl, (g) aroyl, (h) aroyloxy, (i) C1_6alkyl, (j) C1_6allcenyl, (k) Cl_6alkoxy, (1) C1_6allcyl-S(O)k-, wherein k is 0, 1 or 2, (m) C1_6allcyl-C(O)-, (n) C1_6alkoxy-C(O), (o) C1_6alkyl-C(O)-O-, (p) carboxy, (q) hydroxy, (r) N(R8)2, (s) S02R8, and (t) SO2N(R$)2 wherein the alkyl aryl and heterocycle portions of items , alkenyl, (b)-(o) above are optionally substitutedone up to the maximum number of substituable from positions with a member independently selected from the group consisting of: halo, heterocycle, Cl_6allcoxy, Cl_6allcyl-S(O)lz-, wherein k is 0, 1 or 2, Cl_6allcyl-C(O)-, Cl_6alkoxy-C(O)-, C1_6alleyl-C(O)-O-,aralkoxy, carboxy and hydroxy, the alkyl ,portions of said C1_6alkoxy, C1_6alkyl-S(O)k-, C1_6alkyl-C(O)-, C1_6alkoxy-C(O) and C1_6alleyl-C(O)-O groups optionally substituted with 1-3 substituents independently selected from halo and hydroxy;

said aryl and heterocycle portions of items (b)-(h) above further optionally substituted from one up to the maximum number of substituable positions with C1_6alkyl optionally substituted with 1-3 substituents independently selected from the group consisting of: halo and hydroxy;

(2) C1_~allcyl or C1_~allcenyl, each optionally substituted with 1-3 groups independently selected from the group consisting of: halo, hydroxy, C3_ 6cycloalkyl, aryl and heterocycle, said aryl and heterocycle optionally substituted with 1-3 substituents independently selected from:
(a) halo, (b) hydroxy, (c) aryl, optionally substituted with 1-3 halo groups, and (d) C1_6allcyl, optionally substituted independently with 1-3 halo or hydroxy groups, except that when R2 is methyl monosubstituted with aryl as phenyl then R2 is defined as in (1) above, and (3) amyl, optionally substituted with aryloxy or arylthio, said aryloxy or arylthio optionally substituted with 1-3 halo groups;
R3 is selected from the group consisting of:
(1) C1-(alkyl, C2_6alkenyl or C3_6alkynyl, each optionally substituted with 1-3 halo groups, (2) aryl, optionally substituted with 1-3 halo groups, and (3) aralkyl, optionally substituted with a substituent independently selected from the group consisting of: C1_6alkylsulfonyl and halo, R4, R5, R6 and R~ are each independently selected from the group consisting of:
(1) hydrogen, (2) halo, and (3) C1-(alkyl, optionally substituted with 1-3halo .groups, or R3 and R4 may be joined together with the atoms to which they are attached to form a monocyclic ring as shown in Formula A' R~ R1 R5 ~ N O

A' wherein R14 is selected from the groups consisting of: halo, C1-(alkyl or aryl, wherein C1_6allcyl and aryl are optionally substituted with 1-3 halo groups;
and Rg is selected from the group consisting of H, C1_6alkyl, C1_6allcenyl and C1_6alkyl-C(O)-, the alkyl and alkenyl portions of which are optionally substituted with 1-3 halo groups, in an amount which is effective for treating the prostaglandin E mediated disease.
For purposes of this Specification, "pharmaceutically acceptable hydrate" means the compounds of the instant invention crystallized with one or more r molecules of water to form a hydrated form.
For purposes of this Specification, the term "pharmaceutically acceptable ester" means ester derivative formed at any carboxylic acid of the compounds of the present invention, such as Example 55, that may act as a prodrug which, when absorbed into the bloodstream of a warm-blooded animal, may cleave in such a manner as to release the drug form and permit the drug to afford improved therapeutic efficacy.
For purposes of this Specification, "pharmaceutically acceptable tautomer" means any tautomeric form of any compound of the present invention.
For example, the compounds of the present invention would include the tautomeric forms shown below:
OH O O
R R ~ R
~Fi I /
/ ~ / N O N OH

For purposes of this Specification, "treating" a prostaglandin E
mediated disease or condition encompasses not only treating a patient with symptoms of the disease or condition but also "prophylactically treating" a patient prior to that patient manifesting symptoms of the disease or condition to prevent said disease or condition. The term "treating" a prostaglandin disease or condition also encompasses preventing the onset or progression of a prostaglandin E mediated disease or condition.
An embodiment of the invention encompasses the above method wherein the prostaglandin E mediated disease or condition is selected from the group consisting of:
(1) pain, fever or inflammation associated with rheumatic fever, influenza or other viral infections, common cold, low back and neck pain, skeletal pain, post-partum pain, dysmenorrhea, headache, migraine, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns including radiation and corrosive chemical injuries, sunburns, pain following surgical and dental procedures as well as immune and autoimmune diseases;
(2) cellular neoplastic transformations or metastic tumor growth;
(3) diabetic retinopathy and tumor angiogenesis;
(4) prostanoid-induced smooth muscle contraction associated with dysmenorrhea, premature labor, asthma or eosinophil related disorders;
(5) Alzheimer's disease;

(6) glaucoma;

(7) bone loss;

(8) osteoporosis;

(9) promotion of bone formation;
(10) Paget's disease;
(11) cytoprotection in peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or other gastrointestinal lesions;
(12) GI bleeding and patients undergoing chemotherapy;
(13) coagulation disorders selected from hypoprothrombinemia, haemophilia and other bleeding problems;
(14) kidney disease;
(15) thrombosis;
_7_ (16) occlusive vascular disease;
(17) presurgery;
(18) anti-coagulation;
(19) neuropathic pain; and (20) urinary incontinence.
Another embodiment of the invention encompasses the above method wherein the prostaglandin E mediated disease is selected from the group consisting of:
pain, fever or inflammation associated with rheumatic fever, influenza or other viral infections, common cold, low back and neck pain, skeletal pain, post-partum pain, dysmenorrhea, headache, migraine, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns including radiation and corrosive chemical injuries, sunburns, pain following surgical and dental procedures as well as immune and autoimmune diseases.
Another embodiment of the invention encompasses the above method W herein the prostaglandin E mediated disease or condition is pain, fever or inflammation associated with dysmenorrhea.
Another embodiment of the invention encompasses the above method for treating a prostaglandin E mediated disease or condition comprising administering to a mammalian patient in need of such treatment a compound of Formula A:
R~ R1 Rs \ \ R2 R5 / N' 'O

A
or a pharmaceutically acceptable salt thereof, said variables as defined above, wherein the compound of Formula A is co-administered with other agents or ingredients.
Within this embodiment is encompassed the method wherein the compound of Formula A is co-administered with another agent or ingredient selected from the group consisting of:
_g_ (1) an analgesic selected from acetaminophen, phenacetin, aspirin, a narcotic;
(2) a cyclooxygenase-2 selective nonsteroidal anti-inflammatory drug or a conventional nonsteroidal anti-inflammatory drug;
(3) caffeine;
(4) an H2-antagonist;
(5) aluminum or magnesium hydroxide;
(6) simethicone;
(7) a decongestant selected from phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine;
(8) an antiitussive selected from codeine, hydrocodone, caramiphen, carbetapentane and dextramethorphan;
(9) another prostaglandin ligand selected from misoprostol, enprostil, rioprostil, ornoprostol and rosaprostol; a diuretic; and (10) a sedating or non-sedating antihistamine. Examples of COX-2 inhibitors are disclosed in U.S. Patent Nos. 5,474,995; 5,633,272; and 5,466,823; and in WO 96/25405, WO 97/38986, WO 98!03484, WO 97/14691, and WO 95/0051.
Also, within this embodiment is encompassed the method wherein the compound of Formula A is co-administered with a cyclooxygenase-2 selective nonsteroidal anti-inflammatory drug or a conventional nonsteroidal anti-inflammatory drug.
Also within this embodiment is encompassed the method wherein the compound of Formula A is co-administered with a conventional nonsteroidal anti-inflammatory drug selected from the group consisting of: aspirin, ibuprofen, naproxen, and ketoprofen.
Also within this embodiment is encompassed the method wherein the compound is co-administered with a cyclooxygenase-2 selective nonsteroidal anti-inflammatory drug selected from rofecoxib, etoricoxib, valdecoxib, parecoxib and celecoxib.
Another embodiment of the invention encompasses the method for treating a prostaglandin E mediated disease or condition comprising administering to a mammalian patient in need of such treatment a compound of Formula A or a pharmaceutically acceptable salt thereof, wherein R2 is benzyl, optionally substituted with 1-3 substituents independently selected from the group consisting of:
(a) 'halo, (b) aryl, (c) aryloxy, (d) aryl-S(O)1~, wherein lc is 0, 1 or 2, (e) heterocycle, (f) aralkyl, (g) amyl, (h) aroyloxy, (i) C 1 _6alkyl, , (j) C1_6alkenyl, (k) C1_6alkoxy, (1) C1_6alkyl-S(O)k-, wherein k is 0, 1 or 2, (m) C1_6alkyl-C(O)-, (n) C1_6alkoxy-C(O), (o) C1_6allcyl-C(O)-O-, , (p) carboxy, (q) hydroxy, and (r) N(R8)2, wherein the alkyl , alkenyl, aryl and heterocycle portions of items (b)-(o) above are optionally substituted from one up to the maximum number of substituable positions with a member independently selected from the group consisting of: halo, heterocycle, C1_6alkoxy, C1_6alkyl-S(O)k-, C1_6alkyl-C(O)-, C1_6alkoxy-C(O)-, C1-(alkyl-C(O)-O-, aralkoxy, carboxy and hydroxy, the alkyl portions of said C1_6alkoxy, C1_6alkyl-S(O)k-, C1_6alkyl-C(O)-, C1_balkoxy-C(O) and C1_6alkyl-C(O)-O groups optionally substituted with 1-3 substituents independently selected from halo and hydroxy;
said aryl and heterocycle portions of items (b)-(h) above further optionally substituted from one~up to the maximum number of substituable positions with C1_6alkyl optionally substituted with 1-3 substituents independently selected from the group consisting of: halo and hydroxy.

Another embodiment of the invention encompasses the method for treating a prostaglandin E mediated disease or condition comprising administering to a mammalian patient in need of such treatment a compound of Formula A or a pharmaceutically acceptable salt thereof, wherein R2 is mono-, di or tri substituted benzyl, wherein the substituents are independently selected from the group consisting of:
(a) aryl, (b) aryloxy, (c) aryl-S(O)k-, wherein k is 0, 1 or 2, (d) heterocycle, (e) aralkyl, (t7 amyl, and (g) aroyloxy, the aryl and heterocycle portions of items (a)-(g) above are optionally substituted from one up to the maximum number of substituable positions with a member independently selected from the group consisting of: halo, C1_6allcyl, C1_6alkoxy, C1_(alkyl-S(O)k-, C1_6alkyl-C(O)-, C1_6alkoxy-C(O)-, C1_6alkyl-C(O)-O-, aralkoxy, carboxy and hydroxy, the alkyl portions of said C1_6alkoxy, C1_6alkyl-S(O)k-, C1_6alkyl-C(O)-, C1-(alkoxy-C(O) and C1_6alkyl-C(O)-O groups optionally substituted with 1-3 substituents independently selected from halo and hydroxy.
Another embodiment of the invention encompasses the method for treating a prostaglandin E mediated disease or condition comprising administering to a mammalian patient in need of such treatment a compound of Formula A or a pharmaceutically acceptable salt thereof, wherein R2 is mono-, di- or tri-substituted benzyl, with the proviso that at least one of the substituents is attached to the benzyl group at the 4-position.
Another embodiment of the invention encompasses the method for treating a prostaglandin E mediated disease or condition comprising administering to a mammalian patient in need of such treatment a compound of Formula A or a pharmaceutically acceptable salt thereof, wherein R1 is methoxy, difluoromethoxy, hydroxy or amino.
Another embodiment of the invention encompasses the method for treating a prostaglandin E mediated disease or condition comprising administering to a mammalian patient in need of such treatment a compound of Formula A or a pharmaceutically acceptable salt thereof, wherein R3 is benzyl, phenyl, ethyl, propyl, methyl or allyl.
The present invention also encompasses the method for treating a prostaglandin E mediated disease or condition comprising administering to a mammalian patient in need of such treatment a compound from the following tables:
R~ Ri Ri 1 \ \
R5 ~ N O / Ri s Ra "R3 R4 ,' R~ Z2.7'Rxl, RI2', g13 RS ' OMe benzyl H H H H H H H

OH 4-MeSO2benzylH H H H H H H

OH benzyl H H H H H H 4-MeS02 OH n-butyl H H H H H H H

Me benzyl H H H H H H H

OH iso-propylH H H H H H H

OH Me H H H H H H H

OH henyl H H H H H H H

OH Me H H H H H H Me OH Benz 1 Me H H H H H H

OH ethyl Me H H H H H H

OH Me H Cl H H H H henyl OH Me H H Cl H H H 3-Cl-4-F-henyl NH2 Me H H H H F H 3-Cl-4-F-henyl OH Me H H H H H H OMe OH Me H H H H H H C02Me OH Me H H H H H C02H H

OH Me H H H H H H C02H

~OH Me H H H H H H SMe I I

gl g3 ~4 R5 R6 g7 X11 g~2 g13 OH Me H H H H Me H H

OH Me H H H H H Me H

OH Me H H H H H H OPh OH Me H H H H H H Ph OH Me H H H H H H CF3 OH Me H H H H H H F

OH Me H H H H H H NMe2 OH Me H H H H H H iso ro yl OH ethyl H H H H H H Me OH Me H H H H H H 3,4-(OCF2H) OH Me H H H H H H henylsulfonyl OH Me H H H H H H 4-Cl-thio henoxy OH Me H H H H H H benzo 1 OH Me H H H H H H bromo OH Me H H H H H H 3-Cl-4-F-henyl OCF2H Me H H H H H H henyl OH Me H H H H H H 5-(2-Et-yridin 1) OH Me H H H H H 5-(2-Et-H
yridinyl) OH Me H H H H H 4-CF3- H
henyl OH Me H H H H H H 4-CF3- henyl OH Me H H H H H H 4-tert-butyl henyl OH Me H H H H H H 4-ace 1 henyl OH Me H H H H H 4-acetylH
henyl OH Me H H H H H H 4-carboxy henyl OH Me H H H H H H 4-Et- hen OH Me H H H H H bromo H

OMs Me H H H H H H henyl OH Me H H H H H henyl H

OH Me H H H H H 4- H
carbox henyl Rl R3 R4 R5 ~6, ~7 Ril~1~ R13 OH Me H H H H H 4-C1- H
henyl OH Me H H H H H 3-thienylH

OH Me H H H H H 4-OCF3- H
henyl OH Me H H H H H H 3-thienyl OH Me H H H H H H 2-tluenyl OH Me H H H H H H 2-na hthyl OH Me H H H H H H 4-Cl- hen OH Me H H H H H H 4-OCF3- henyl OH Me H H H H H H 2-benzothio hene OH Me H H H H H H 4-F- henyl OH Me H H H H H 2-F- H
henyl OH Me H H H H H H 4-Me- henyl OH Me H H H H H H 4-benzyloxy henyl OH Me H H H H H H a-OH-a-Me-benzyl OH Me H H H H H H 1-na hthyl OH Me H H H H H H 2-F- henyl OH Me H H H H H H 3-F- henyl OH Me H H H H H H 3-Cl- henyl OH Me H H H H H 3-Cl-phenylH

OH Me H H H H H 3-F- H
henyl OH Me H H H H H H 4-Cl- henylsulfonyl OH Me H H H H H H a-OH-a-Me-4-Cl-benz 1 OH Me H H H H H H 3-Cl-4-F-henyl OH eth 1 H H H H H H 3-Cl-4-F-henyl OH allyl H H H H H H 3-Cl-4-F-hen 1 OH n- ro H H H H H H 3-Cl-4-F-phen yl 1 OH Me H H H H H H 4-MeS02 OH Me H H H H H 2- H
benzothio hene OH 4-C1-benzylH H H H H H 3-C1-4-F-henyl gl g3 g4 RS R6 g7 g11 g12 g13 NH2 Me H H H H H H 3-C1-4-F-henyl 2-(2- Me H H H H H H 3-Cl-4-F-phenyl yridinyl)ethoxy carbethoxymethoxyMe H H H H H H 3-Cl-4-F-henyl n-btttoxy Me H H H H H H 3-Cl-4-F-henyl 2-(Methio)ethoxyMe H H H H H H 3-Cl-4-F-henyl O-(3,4-F-benzoyl)Me H H H H H H 3-Cl-4-F-henyl OAc Me H H H H H H 3-Cl-4-F-henyl C1 Me H H H H H H 3-Cl-4-F-henyl OCF2H Me H H H H H H hen lsulfonyl OMs Me H H H H H H 3-Cl-4-F-henyl carbox Me H H H H H H 3-Cl-4-F-methoxy henyl OCF2H Me H H H H H H bromo OCF2H Me H H H H H Bromo H

OH Me H H H H H H dimethylcarbinol OCF2H Me H H H H H H 4-Me- henyl ' OCF2H Me H H H H H H 3-Me- henyl OCF2H Me H H H H H 4-Me- H
henyl OCF2H Me H H H H H 3-Me- H
henyl NH2 Me H H H H H H Me OH Me H H H H H C02Et H

OCF2H allyl H H H H H H 3-Cl-4-F-hen 1 OH 2-Me-2- H H H H H H 3-Cl-4-F-ropene henyl OH Me H H H H H DimethylcarbinH
of OH ro ar H H H H H H 3-Cl-4-F-yl henyl OH 2-bromo-2-H H H H H H 3-Cl-4-F
ro ene OH allyl H H H H H H 4-Cl-thio henoxy OCF2H all 1 H H H H H H 4-Cl-thio henoxy Me2N Me H H H H H H Me g1 R3 g4 RS g6 g7 R11g12 g13 NHAc Me H H H H H H Me NH2 allyl H H H H H H 4-Cl-thio henoxy NHallyl allyl H H H H H H 4-Cl-thio henoxy NH2 Me H H H H H H bromo 2-hydroxyethoxyMe H H H H H H 3-Cl-4-F-henyl NH2 2,2,2- H H H H H H 3-C1-4-F-phenyl trifluoroethyl NH2 Me H H H H H H henyl NH2 Me H H H H H H 4-MeS- henyl NH2 Me H H H H H H 4-MeS02-henyl NH2 allyl H H H H H H 3-Cl-4-F-hen 1 NH2 allyl H H H H H H 4-MeSO- hen NH2 allyl H H H H H H 4-MeS02-henyl NH2 Me H H H H H H 4-dimethylcarbinolpheny R~ R1 R6 \ \ R2 N~O
R
R4 'Rs R4=H; R5=H, R6=H; R~=H
~1 R2 g3 OH Me benz 1 OH n-butyl benzyl OH tert-butyl benzyl OH henet 1 benz 1 OH isobutyl benzyl OH a-methylbenzyl benzyl OH benzoyl benzyl OMe benzoyl benzyl OH a-hydroxybenzyl benzyl OH cyclohexyhnethyl methyl OH na hth lmethyl methyl OH n-he tyl methyl OH n-but 1 methyl OH 3- hen 1-2- ro enylmethyl OH 3- henyl- ro yl methyl OH henethyl methyl OH 1-na hth lmethyl methyl OH 4-(4-Cl-thio henoxy)benzoylmethyl NH2 2-(3-Cl-4-F- henyl)-5-meth 1 icolyl OH H

OMe H

OBn H

OH Meth 1 OH Phenyl OMe Phenyl H Phen 1 Another embodiment of the invention encompasses a compound of Formula B
R~ R1 R
-~ R10)2 5 ~ /
R N O X
Ra. Rs B
or a pharmaceutically acceptable salt, hydrate, ester or tautomer thereof, wherein:
X is selected from a bond, O or S(O)k, wherein k is 0, 1 or 2, R1 is selected from the group consisting of:

(1) hydrogen, (2) halo, (3) hydroxy, (4) C1_6alkyl, (5) C1_6alkenyl, (6) C1_6alkoxy, (7) C1_6alkyl-S(O)m-, wherein m is 0, 1, 2 or 3 (8) C1_6alkyl-C(O)_ (7) C1_6alkoxy-C(O)-(9) C1_6alkyl-C(O)-O-(10) aryl, (11) aralkyl, (12) aryloxy, (13) arallcoxy, (14) arylthio, (15) aroyl, (16) aroyloxy and (17) N(R8)2, wherein the alkyl , allcenyl and aryl portions of items (4)-(16) above are optionally substituted from one up to the maximum number of substituable positions with a member independently selected from the group consisting of: halo, heterocycle, C1_ (alkoxy, C1_6allcyl-S(O)1~-, C1_6alkyl-C(O)-, C1_6allcoxy-C(O), C1_~alkyl-C(O)-O, carboxy, hydroxy and aralkoxy, the alkyl portions of said C1_6allcoxy, C1_6allcyl-S(O)h-, C1_galkyl-C(O)-, C1_6allcoxy-C(O) and C1_6allcyl-C(O)-O groups optionally substituted with 1-3 substituents independently selected from: halo and hydroxy, said aryl portions of items (10)-(16) above further optionally substituted from one up to the maximum number of substituable positions with C1_6alkyl, optionally substituted with 1-3 substituents independently selected from the group consisting of:
halo and hydroxy;
R3 is selected from the group consisting of:
(1) C1_6alkyl, CZ_6allcenyl or C3-(alkynyl, each optionally substituted with 1-3 halo groups.
(2) aryl, optionally substituted with 1-3 halo groups, (3) aralkyl, optionally substituted with a substituent independently selected from the group consisting of: C1_6allcylsulfonyl and halo, R4, R5, R6 and R7 are each independently selected from the group consisting of:
(1) hydrogen, (2) halo, and (3) C1_6alkyl, optionally substituted with 1-3 halo groups, or R3 and R4 may be joined together with the atoms to which they are attached to form a monocyclic ring as shown in Formula B':

R6 \ \ ~~R )2 Rio / - ~ )2 R

B' wherein R14 is selected from the groups consisting of: halo, C1-(alkyl, aryl or heterocycle, wherein C1_(alkyl, heterocycle and aryl are optionally substituted with 1-3 substituents independently selected from halo, C1_3alkyl, carboxy, S02C1_3alkyl or S02N(C1_3alliyl)2 , said C1_3alkyl is optionally substituted with a hydroxy group, and R8 is selected from the group consisting of H, C1_6allcyl, C1_6alkenyl, C1_6allcyl-C(O)- and aryl, the aryl, alkyl and alkenyl portions are optionally substituted with 1-3 halo groups, R9 and R10 are independently selected from the group consisting of:
(1) halo, (2) C1_6alkyl, (3) C1_6alkenyl, (4) C1_6allcoxy, (5) C1_6alkyl-S(O)k-, wherein k is 0, 1 or 2, (6) C1_6alkyl-C(O)-, (~) C1-6allcoxy-C(O), (8) C1_6alkyl-C(O)-O-, (9)carboxy, (10)hydroxy, and (11)N(R8)2, wherein the alkyl and alkenyl portions of items (2)-(8) above are optionally substituted from one up to the maximum number of substituable positions with a member independently selected from the group consisting of: halo, heterocycle, 6alkoxy, C1_6alkyl-S(O)k-, C1_6alkyl-C(O)-, C1-(alkoxy-C(O)-, C1_6alkyl-C(O)-O-, aralkoxy, carboxy and hydroxy, the alkyl portions of said C1_6alkoxy, C1_6alkyl-S(O)1{-, C1_6allcyl-C(O)-, C1_~alkoxy-C(O) and C1_6alkyl-C(O)-O groups optionally substituted with 1-3 substituents independently selected from halo and hydroxy.
Within this embodiment is encompassed the compound of Formula B
wherein:
X is selected from a bond, O or S(O)k, wherein k is 0, 1 or 2, R1 is selected from the group consisting of:
(1) halo, (2) hydroxy, (3) C1_6allcyl, (4) C1_6allcoxy, and (5) N(Rg)2, wherein Rg is H or C1_q.alkyl, wherein the alkyl portions of items (3)-(4) above are optionally substituted with 1-3 halo groups, R3 is C1_6alkyl or C2_q.allcenyl, each optionally substituted with 1-3 halo groups.
R4, R5, R6, R~ and R9 are each H, and R10 is H or halo.
The present invention also encompasses a compound selected from the group consisting of:
(1) 3-{4-[(4-chlorophenyl)thio]benzyl}-4-hydroxy-1-methylquinolin-2(lI~-one;
(2) 1-allyl-3-{4-[(4-chlorophenyl)thio]benzyl}-4-hydroxyquinolin-2(1F~-one;
(3) 1-allyl-4-amino-3-{4-[(4-chlorophenyl)thio]benzyl}quinolin-2(lI~-one;
(4) 3-[(3'-chloro-4'-fluoro-1,1'-biphenyl-4-yl)methyl]-4-hydroxy-1-methylquinolin-2(1H)-one;
(5) 1-allyl-3-[(3'-chloro-4'-fluoro-1,1'-biphenyl-4-yl)methyl]-4-hydroxyquinolin-2(lI~-one;
(6) 4-amino-3-[(3'-chloro-4'-fluoro-l,1'-biphenyl-4-yl)methyl]-1-methylquinolin-2( l I~-one;
(7) 3-[(3'-chloro-4'-fluoro-1,1'-biphenyl-4-yl)methyl]-4-(difluoromethoxy)-1-methylquinolin-2(1I~-one; and (8) 3-{4-[(4-chlorophenyl)sulfonyl]benzyl}-4-hydroxy-1-methylquinolin-2(lI~-one.
Another embodiment of the invention encompasses a pharmaceutical composition comprising a compound of Formula B in combination with a pharmaceutically acceptable carrier.
The invention is described using the following definitions unless otherwise indicated.
The term "halogen" or "halo" includes F, Cl, Br, and I.
The term "alkyl" means linear or branched structures and combinations thereof, having the indicated number of carbon atoms. Thus, for example, C1-(alkyl includes methyl, ethyl, -propyl, 2-propyl, s- and t-butyl, butyl, pentyl, hexyl, 1,1-dimethylethyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
The term "alkoxy" means alkoxy groups of a straight, branched or cyclic configuration having the indicated number of carbon atoms. C1_6alleoxy, for example, includes methoxy, ethoxy, propoxy, isopropoxy, and the like.
The term "alkylthio" means alkylthio groups having the indicated number of carbon atoms of a straight, branched or cyclic configuration. C1_ (alkylthio, for example, includes methylthio, propylthio, isopropylthio, and the like.
The term "alkenyl" means linear or branched structures and combinations thereof, of the indicated number of carbon atoms, having at least one carbon-to-carbon double bond, wherein hydrogen may be replaced by an additional carbon-to-carbon double bond. CZ-~alkenyl, for example, includes ethenyl, propenyl, 1-methylethenyl, butenyl and the like.
The term "allcynyl" means linear or branched structures and combinations thereof, of the indicated number of carbon atoms, having at least one carbon-to-carbon triple bond. C3-(allcynyl, for example, includes , propenyl, methylethenyl, butenyl and the like.
The team "cycloalkyl" means mono-, bi- or tri-cyclic structures, optionally combined with linear or branched structures, the indicated number of carbon atoms. Examples of cycloalkyl groups include cyclopropyl, cyclopentyl, cycloheptyl, adamantyl, cyclododecylmethyl, 2-ethyl-1- bicyclo[4.4.0]decyl, and the like.
The term "aryl" is defined as a mono- or bi-cyclic aromatic ring system and includes, for example, phenyl, naphthyl, and the like.
The term "aralkyl" means an alkyl group as defined above of 1 to 6 carbon atoms with an aryl group as defined above substituted for one of the alkyl hydrogen atoms, for example, benzyl and the like.
The term "aryloxy" means an aryl group as defined above attached to a molecule by an oxygen atom (aryl-O) and includes, for example, phenoxy, naphthoxy and the like.
The term "aralkoxy" means an aralkyl group as defined above attached to a molecule by an oxygen atom (aralkyl-O) and includes, for example, benzyloxy, and the like.
The term "arylthio" is defined as an aryl group as defined above attached to a molecule by an sulfur atom (aryl-S) and includes, for example, thiophenyoxy, thionaphthoxy and the like.
The term "aroyl" means an aryl group as defined above attached to a molecule by an carbonyl group (aryl-C(O)-) and includes, for example, benzoyl, naphthoyl and the like.
The term "aroyloxy" means an amyl group as defined above attached to a molecule by an oxygen atom (aroyl-O) and includes, for example, benzoyloxy or benzoxy, naphthoyloxy and the like.
The term "heterocycle" is defined as a 5- to 10-membered aromatic, partially aromatic or non-aromatic mono- or bicyclic ring, containing 1-3 heteroatoms selected from O, S and N, and optionally substituted with 1-2 oxo groups.
Preferably, "heterocycle" is a 5- or 6-membered aromatic or non-aromatic monocyclic ring containing 1-3 heteroatoms selected from O, S and N, for example, pyridine, pyrimidine, pyridazine, furan, thiophene, thiazole, oxazole, isooxazole and the like, or heterocycle is a 9- or 10-membered aromatic or partially aromatic bicyclic ring containing 1-3 heteroatoms selected from O, S, and N, for example, benzofuran, benzothiophene, indole, pyranopyrrole, benzopyran, quionoline, benzocyclohexyl, naphtyridine and the like. "Heterocycle" also includes the following:
benzimidazolyl, benzofuranyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropynolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl.
For purposes of this specification, the following abbreviations have the indicated meanings:
BOC - t-butyloxycarbonyl Bn - benzyl CBZ - carbobenzoxy DCC - 1,3-dicyclohexylcarbodiimide DCM - dichloromethane DIBAL - diisobutyl aluminum hydride DIEA - N,N-diisoproylethylamine DMAP - 4-(dimethylanuno)pyridine EDCI - 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride EDTA - ethylenediaminetetraacetic acid, tetrasodium salt hydrate FAB - fast atom bombardment FMOC - 9-fluorenylmethoxycarbonyl HMPA - hexamethylphosphoramide HATU - O-(7-Azabenzotriazol-1-yl)N,N,N',N'-tetramethyluronium hexafluorophosphate HOBt - 1-hydroxybenzotriazole HRMS - high resolution mass spectrometry ICBF - isobutyl chloroformate I~I~VIDS - potassium hexamethyldisilazane LDA - lithium diisopropylamide MCPBA - metachloroperbenzoic acid Ms - methanesulfonyl = mesyl Ms0 - methanefulfonate = mesylate NBS - N-bromosuccinimide NMM - 4-methylmorpholine PCC - pyridinium chlorochromate PDC - pyridinium dichromate Ph - phenyl PPTS - pyridinium p-toluene sulfonate pTSA - p-toluene sulfonic acid r.t. - room temperature rac. - racemic Tf0 - trifluoromethanesulfonate = triflate THF - tetrahydrofuran TLC - thin layer chromatography Alkyl group abbreviations Me - methyl Et - ethyl n-Pr - normal propyl i-Pr - isopropyl n-Bu - normal butyl i-Bu - isobutyl s-Bu - secondary butyl t-Bu - tertiary butyl Salts The pharmaceutical compositions of the present invention comprise a compound of Formula A or B as an active ingredient or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts"
refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, malefic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like. Particularly preferred are citric, hydrobromic, hydrochloric, malefic, phosphoric, sulfuric, and tartaric acids.
It will be understood that in the discussion of methods of treatment which follows, references to the compounds of Formula A or B are meant to also include the pharmaceutically acceptable salts.
Dose Ranges The magnitude of prophylactic or therapeutic dose of a compound of Formula A or B will, of course, vary with the nature and the severity of the condition to be treated and with the particular compound of Formula A and its route of administration. It will also vary according to a variety of factors including the age, weight, general health, sex, diet, time of administration, rate of excretion, drug combination and response of the individual patient. In general, the daily dose from about 0.001 mg to about 100 mg per kg body weight of a mammal, preferably 0.01 mg to about 10 mg per kg. On the other hand, it may be necessary to use dosages outside these limits in some cases.
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain between from about 1 mg to about 2 g of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, mg, 800 mg, or 1000 mg.
Pharmaceutical Compositions For the treatment of any of the prostanoid mediated diseases compounds of Formula A or B may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc., the compound of the invention is effective in the treatment of humans.
The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water-miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
Sweetening agents such as those set forth above, and flavouring agents may be added to ,provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsion. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.
Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known 9_ art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
Compounds of Formula A or B may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at , ambient temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
For topical use, creams, ointments, gels, solutions or suspensions, etc., containing the compound of Formula A or B are employed. (For purposes of this application, topical application shall include mouth washes and gargles.) Topical formulations may generally be comprised of a pharmaceutical carrier, cosolvent, emulsifier, penetration enhancer, preservative system, and emollient.
Utilities The ability of the compounds of Formula A or B to interact with prostaglandin receptors makes them useful for preventing or reversing undesirable symptoms caused by prostaglandins in a mammalian, especially human subject.
This mimicl~ing or antagonism of the actions of prostaglandins indicates that the compounds and pharmaceutical compositions thereof are useful to treat, prevent, or ameliorate in mammals and especially in humans: Pain, fever and inflammation of a variety of conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low baclc and neck pain, skeletal pain, post-partum pain, dysmenorrhea, headache, migraine, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns including radiation and corrosive chemical injuries, sunburns, pain following surgical and dental procedures as well as immune and autoimmune diseases. In addition, such a compound may inhibit cellular neoplastic transformations and metastic tumor growth and hence can be used in the treatment of cancer. Compounds of formula A
may also be of use in the treatment andlor prevention prostaglandin E mediated proliferation disorders such as may occur in diabetic retinopathy and tumor angiogenesis. Compounds of Formula A or B will also inhibit prostanoid-induced smooth muscle contraction by antagonizing contractile prostanoids or mimicking relaxing prostanoids and hence may be use in the treatment of dysmenorrhea, premature labor, asthma and eosinophil related disorders. It will also be of use in the treatment of Alzheimer's disease, the treatment of glaucoma, for the prevention of bone loss (treatment of osteoporosis) and for the promotion of bone formation (treatment of fractures) and other bone diseases such as Paget's disease.
The compounds of the present invention are also useful for treating neuropathic pain and urinary incontinence.
By virtue of its prostanoid or prostanoid antagonist activity, a compound of Formula A or B will prove useful as an alternative to conventional non-steroidal anti-inflammatory drugs (NSATI~'S) particularly where such non-steroidal anti-inflammatory drugs may be contraindicated such as in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; GI bleeding, coagulation disorders including anemia such as hypoprothrombinemia, haemophilia or other bleeding problems; kidney disease;
thrombosis, occlusive vascular diseases; those prior to surgery or taking anti-coagulants. Compounds of Formula A or B will also be useful as a cytoprotective agent for patients under chemotherapy.
_Combinations with Other Drugs Compounds of Formula A or B will be useful as a partial or complete substitute for conventional antiinflammatory or analgesic compounds in preparations wherein they are presently co-administered with other agents or ingredients.
Thus in further aspects, the invention encompasses pharmaceutical compositions for treating prostaglandin E2 mediated diseases as defined above comprising a non-toxic therapeutically effective amount of the compound of Formula A or B as defined above and one or more ingredients such as another pain reliever including acetaminophen or phenacetin; a COX-2 selective inhibiting agent; a conventional NSAID; a potentiator including caffeine; an H2-antagonist, aluminum or magnesium hydroxide, simethicone, a decongestant including phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine; an antiitussive including codeine, hydrocodone, caramiphen, carbetapentane, or dextramethorphan; another prostaglandin ligand including misoprostol, enprostil, rioprostil, ornoprostol or rosaprostol; a diuretic; a sedating or non-sedating antihistamine. In addition, the invention encompasses a method of treating prostaglandin E2 mediated diseases comprising: administration to a patient in need of such treatment a non-toxic therapeutically effective amount of the compound of Formula A, optionally co-administered with one or more of such ingredients as listed immediately above.
METHODS OF SYNTHESIS
Compounds of the present invention can be prepared according to the following methods.
Compounds of the present invention can be prepared according to the methods described in patent WO 92/04327, published March 19, 1992, U.S. No. 5,942,522, granted August 24, 1999, U.S. No. 5,412,104, granted May 2, 1995, U.S. No.
5,378,694, granted January 3, 1995, all of which are hereby incorporated by reference in their entirety, or by the following methods:
Method A
The examples may be prepared by reductive allcylation at C3 of the commercially available N-methyl-4-hydroxy-2-quinolinone with various aldehydes OH OH
RCHO I \ \ R2 \ \
/ N~O H+, R3SiH / N' 'O
Rs R3 II
using an acid such as TFA or formic acid with a reducing agent such as Et3SiH
in a solvent such as toluene, acetonitrile or formic acid.

Method B
Compound of formula III (for example alkyl anthranilate or anthranilonitrile) can be used to make amino or hydroxy-quinolinone by sequential allcylation of amino group with alkylating agents such as acid chloride and alkyl halide using standard protocols.
Cyclization to the quinolinone can be performed with a base such as potassium tert-butoxide in a solvant such as THF.
1. R2CH2COCI, base X

\ 2. R3X, base \ E O base _ \ \ R
~/
NH2 3 N CH2R2 ~ N O
1. R X, base R3 Rs E= C02R, CN 2~ R2CH2COCI, base ~V A X= OH, NH2 Method C
Compound of formula A' may be prepared by reacting indoline (from commercial sources of via reduction of corresponding indoles (see for ex. B.F.
Bowden et al, Aust. J. Chem., 1975, 28, 65-80) with malonates (see T.Kappe, C.O.Kappe, J.Heterocyclic Chem.,1989, 26, 1555).
\ OH
z R2CH2CH(CO2R')2 I \ \ R
'NH
I 4 / N ~O
R ~ ~-I
V Ria REPRESENTATIVE COMPOUNDS
Table 1 illustrates compounds which are representative of the present invention.
Table 1 R~ R1 R11 Rs -~ N ~~ ~ R13 Ei~am R1 R3 ;R4,g5, R6 ,;,.R7g11X12 : ~ g13 le 1 OMe benzyl H H H H H H H

2 OH 4-MeS02benzylH H H H H H H

3 OH benzyl H H H H H H 4-MeSO2 4 OH n-but H H H H H H H

Me benzyI H H H H H H H

6 OH iso- H H H H H H H
ro yl 7 OH Me H H H H H H H

8 OH henyl H H H H H H H

16 OH Me H H H H H H Me 17 OH benzyl Me H H H H H H

18 OH ethyl Me H H H H H H

19 OH Me H Cl H H H H henyl 20 OH Me H H Cl H H H 3-Cl-4-F-henyl 21 NH2 Me H H H H F H 3-Cl-4-F-henyl 22 OH Me H H H H H H OMe 23 OH Me H H H H H H C02Me 24 OH Me H H H H H C02H H

25 OH Me H H H H H H C02H

26 OH Me H H H H H H SMe 27 OH Me H H H H Me H H

>rxami Rl R3 R4 RS R6 R7 RllR12 R13 le 28 OH Me H H H H H Me H
29 OH Me H H H H H H OPh 30 OH Me H H H H H H Ph 31 OH Me H H H H H H CF3 32 OH Me H H H H H H F
33 OH Me H H H H H H NMe2 34 OH Me H H H H H H iso ro yl 35 OH ethyl H H H H H H Me 36 OH Me H H H H H H 3,4-(OCF2H) 37 OH Me H H H H H H henylsulfonyl 38 OH Me H H H H H H 4-Cl-thio henoxy 39 OH Me H H H H H H benzoyl 40 OH Me H H H H H H bromo 41 OH Me H H H H H H 3-Cl-4-F-henyl 42 OCF2H Me H H H H H H henyl 43 OH Me H H H H H H 5-(2-Et- yridinyl) 44 OH Me H H H H H 5-(2-Et-H
yridin 1) 45 OH Me H H H H H 4-CF3- H
henyl 46 OH Me H H H H H H 4-CF3- hen 47 OH Me H H H H H H 4-tert-butyl henyl 48 OH Me H H H H H H 4-acetylphenyl 49 OH Me H H H H H 4-acetylH
henyl 50 OH Me H H H H H H 4-carbox henyl 51 OH Me H H H H H H 4-Et- hen 52 OH Me H H H H H bromo H
53 OMs Me H H H H H H henyl 54 OH Me H H H H H henyl H
55 OH Me H H H H H 4- H
carbox hen I
56 OH Me H H H H H 4-Cl- H
henyl -3 ~-Exam Rl ~3 R4 g5 g6 g7 Rllg12 g13 le 57 OH Me H H H H H 3-thienylH
58 OH Me H H H H H 4-OCF3- H
henyl 59 OH Me H H H H H H 3-thienyl 60 OH Me H H H H H H 2-thienyl 61 OH Me H H H H H H 2-na hthyl 62 OH Me H H H H H H 4-Cl- henyl 63 OH Me H H H H H H 4-OCF3- henyl 64 OH Me H H H H H H 2-benzothio hene 65 OH Me H H H H H H 4-F- henyl 66 OH Me H H H H H 2-F- henylH
67 OH Me H H H H H H 4-Me- hen 68 OH Me H H H H H H 4-benzyloxy henyl 69 OH Me H H H H H H a-OH-a-Me-benzyl 70 OH Me H H H H H H 1-na hthyl 71 OH Me H H H H H H 2-F- henyl 72 OH Me H H H H H H 3-F- henyl 73 OH Me H H H H H H 3-Cl- henyl 74 OH Me H H H H H 3-Cl- H
henyl 75 OH Me H H H H H 3-F- henylH
76 OH Me H H H H H H 4-Cl- henylsulfonyl 77 OH Me H H H H H H oc-OH-a-Me-4-Cl-benz 1 78 OH Me H H H H H H 3-Cl-4-F-henyl 79 OH ethyl H H H H H H 3-Cl-4-F-henyl 80 OH allyl H H H H H H 3-Cl-4-F-henyl 81 OH n- ro H H H H H H 3-Cl-4-F-1 henyl 82 OH Me H H H H H H 4-MeS02 83 OH Me H H H H H 2- H
benzothio hene 84 OH 4-CI-benzylH H H H H H 3-C1-4-F-henyl 85 NH2 Me H H H H H H 3-C1-4-F-henyl Exam R1 R3 g4 R5 R6 R7 gllR12 g13 le 8G 2-(2- Me H H H H H H 3-C1-4-F-phenyl yridinyl)ethoxy 87 carbethoxymethoxyMe H H H H H H 3-Cl-4-F-henyl 88 n-butoxy Me H H H H H H 3-Cl-4-F-henyl 89 2-(Methio)ethoxyMe H H H H H H 3-Ci-4-F-' henyl 90 O-(3,4-F-benzoyl)Me H H H H H H 3-Cl-4-F-henyl 91 OAc Me H H H H H H 3-Cl-4-F-henyl 92 C1 Me H H H H H H 3-Cl-4-F-henyl 93 OCF2H Me H H H H H H henylsulfonyl 94 OMs Me H H H H H H 3-Cl-4-F-henyl 95 carboxymethoxyMe H H H H H H 3-Cl-4-F-henyl 96 OCF2H Me H H H H H H bromo 97 OCF2H Me H H H H H bromo H

98 OH Me H H H H H H dimethylcarbinol 99 OCF2H Me H H H H H H 4-Me- henyl 100 OCF2H Me H H H H H H 3-Me- henyl 101 OCF2H Me H H H H H 4-Me- H
henyl 102 OCF2H Me H H H H H 3-Me- H
henyl 103 NH2 Me H H H H H H Me 104 OH Me H H H H H C02Et H

105 OCF2H allyl H H H H H H 3-Cl-4-F-henyl 106 OH 2-Me-2- H H H H H H 3-Cl-4-F-ro ene henyl 107 OH Me H H H H H dimethylcarbinH
of 108 OH ro ar H H H H H H 3-Cl-4-F-yl henyl 109 OH 2-bromo-2-H H H H H H 3-Cl-4-F
pro ene 110 OH allyl H H H H H H 4-Cl-thio henoxy 111 OCF2H all 1 H H H H H ~ H 4-Cl-thio henox 112 Me2N Me H H H H H H Me 113 NHAc Me H H H H H H Me Rxam Rl R3 R4 RS R6 R7 RllR12 R13 le 114 NH2 allyl H H H H H H 4-C1-thio henoxy 115 NHall 1 allyl H H H H H H 4-Cl-thio henoxy 11 NH2 Me H H H H H H bromo G

117 2-hydroxyethoxyMe H H H H H H 3-Cl-4-F-henyl 118 NH2 2,2,2- H, H H. H H H 3-C1-4-F-phenyl trifluoroethyl 119 NH2 Me H H H H H H henyl 120 NH2 Me H H H H H H 4-MeS- henyl 121 NH2 Me H H H H H H 4-MeS02-henyl 122 NH2 allyl H H H H H H 3-Cl-4-F-henyl 123 NH2 allyl H H H H H H 4-MeSO- hen 124 NH2 allyl H H H H H H 4-MeS02-henyl 125 NH2 Me H H H H H H 4-dimethylcarbinolpheny l Table 2 further illustrates compounds which are representative of the present invention.
Table 2 R~ R1 R6 \ \ R2 R5 ~ / N
O
R4 'Rs R4=H; R5=H, R6=H; R~=H
a Exam ~1_ Ry R3 le -126 OH Me benzyl 127 OH n-butyl benzyl 128 OH tert-butyl benzyl 129 OH henetyl benzyl 130 OH isobutyl benzyl 131 OH a-methylbenzyl benzyl 132 OH benzoyl benzyl 133 OMe benzoyl benz 1 134 OH a-hydroxybenz 1 benzyl 135 OH cyclohexylmethyl methyl 136 OH na hthylmethyl methyl 137 OH n-he tyl methyl 138 OH n-butyl methyl 139 OH 3- henyl-2- ro enylmethyl 140 OH 3- henyl- ro yl methyl 141 OH henethyl meth 1 142 OH 1-na hthylmethyl meth 1 143 OH 4-(4-Cl-thio henox meth 1 )benzoyl 144 NH2 2-(3-Cl-4-F-phenyl)-5-picolylmethyl Table 3 further illustrates compounds which are representative of the present invention.
Table 3 Exam le RL R14;:

g OH H

10 OMe 11 OBn H

12 OH Meth 1 13 OH Phenyl 14 OMe Phenyl H Phenyl The invention will now be illustrated in the following non-limiting 15 Examples in which, unless otherwise stated:
1. All the end products of the Formula A and intermediates were analyzed by NMR
and TLC;
2. Most compounds were purified by flash chromatography on silica gel, recrystallizati0n and/or swish (stirring vigorously a suspension in a solvent followed by filtration of the solid); and 3. The course of reactions was followed by thin layer chromatography (TLC) and reaction times are given for illustration only.
General procedure:
Method A
To N-methyl-4-hydroxy-2-quinolone (0.5 g, 2.8 mmol) and an aldehyde (4.3 mmol) in toluene (20 mL) at 22°C was added triethylsilane (1.4 mL, 8.8 mmol) and TFA
(1.0 mL, 13 mmol). The reaction mixture was stirred at reflux for 3 h, cooled to 22°C and poured into aqueous NaHC03 and extracted with EtOAc. The organic extract was washed (H20, brine), dried (MgS04), filtered and concentrated.
Purification by flash chromatography or crystallization from hexane-EtOAc (or hexane-Et20) afforded the title compound.
Method B
Step 1 To a stirred solution of the acyl chloride (1.1 eq) in DCM (0.5 M) at room temperature was added anthranilonitrile (1 eq). After 15 minute, triethylanune (1.5 eq) was added and the mixture stirred overnight. The product is filtered off and the filtrate is diluted with ethyl acetate, extracted with water and a saturated solution of ammonium chloride. Purification was by flash chromatography or crystallization from hexane-EtOAc (or hexane-Et2O).
Step 2 The compound from step 1 was suspended in THF at room temperature and then treated with a solution of potassium tert-butoxide in THF (1 eq), stirred 20 minutes then methyl iodide (1 eq) was added, the progress of the alkylation is followed by TLC. When completed, the reaction was treated again with a solution of potassium tert-butoxide in THF (1 eq). After completion by TLC, the reaction mixture is diluted with ethyl acetate and water, washed with a saturated solution of ammonium chloride, a saturated solution of sodium chloride. Purification by flash chromatography or crystallization from hexane-EtOAc (or hexane-Et20) afforded the title compound.

5 Benzyl 6 h~droxy 2-phenyl-1 2-dihydro-pyrrolof3 2 1-iil~uinolin-4-one 2-Phenylindoline and diethylbenzyl malonate was heated to 140°C
over 1 h distilling off EtOH. The mixture was gradually heated up to 280°C and maintained at this temperature for 2 h. Cooling afforded a solid which was stirred vigourously in hot ethyl acetate for 1 h. The desired compound was isolated after filtration as a beige solid. m.p. 252-254°C

OH
4 hydroxy K.1 methyl 3-(4-methylbenzyl)eluinolin-2(lI~-one Following the procedures described in General Method A and using 4 rnethylbenzaldehyde, the title compound was '~ isolated as white powder after purification by flash chromatography (hexane-ethyl acetate, 8:2). An alternative procedure is General Method B, replacing anthranilonitrile with methyl 2-aminobenzoate and 3-(4-methylphenyl)propanoyl chloride.
1H NMR (400 MHz, acetone-d6): 810.1 (s, OH), 8.09 (d, 1H), 7.56 (t, 1H), 7.54 (d, 1H), 7.22 (m, 3H), 7.0 (d, 2H), 4.0 (s, 2H), 3.6 (s, 3H), 2.03 (s, 3H).

OH
CI
'N' ~~O v 'S
3 ~4 f (4 chlorophenyl)thiolbenzyl?-4-hydroxy-1-methylauinolin-2(lI~-one Following the procedures described in General Method A and using 4-[(4-chlorophenyl)thio]benzaldehyde from example 114, stepl, the title compound was isolated as white powder after purification by flash chromatography (hexane-ethyl acetate, 3:2).
1H NMR (400 MHz, DMSO-dg): 8 10.5 (s, 1H), 8.02 (d, 1H), 7.62 (t, 1H), 7.48 (d, 1H), 7.36 (d, 2H), 7.29 (m, 5H), 7.17 (d, 2H), 3.98 (s, 2H), 3.58 (s, 3H).

OH
CI
~N' ~O v ~S

_1 allyl 3 ~4 f(4 chlorophen~)thiolbenzyl~-4-hydroxyauinolin-2(lI~-one Following the procedures described in Example 114, replacing anthranilonitrile with methyl 2-aminobenzoate in step 1 of General Method B, the title compound was isolated as white powder after purification by flash chromatography (hexane-ethyl acetate, 8:2).
1H NMR (400 MHz, acetone-dg): & 8.03 (d, 1H), 7.55 (t, 1H), 7.43-7.34 (m, 4H), 7.30-7.14 (m, 6H), 5.87 (m, 1H), 5.09 (d, 1H), 4.93-4.86 (m, 3H), 3.98 (d, 2H).

\ I CI
,N. ~-1 allyl 4 amino 3 ~4 f(4-chlorophenyl)thiolbenzyllquinolin-2(lI~-one Stepl: 4-f (4-chlorophenyl)thiolbenzaldehyde A solution of 4-fluoro-benzaldehyde (1 eq), 4-chloro-benzenethiol (1.0 eq) and sodium carbonate (1.5 eq) in DMF (0.16 M) was heated at 100°C
for 3h then 18h at rt. The mixture was diluted with ether and water, the organic phase washed with brine and the solvents evaporated. The residue was purified by stirring vigorously in hexane-ether followed by filtration to give the title compound as a white solid.
Step2: methyl (2E~-3-(4-f (4-chloro~henyl)thiolphenyl~prop-2-enoate A solution of aldehyde (1 eq) from stepl and methyl triphenylphosphoranylidene acetate (1.4 eq) in toluene (0.3M) was heated at100°C
for 4h. After evaporatation of the solvents, the residue was purified by flash chromatography (hexane-ethyl acetate, 9:1) to give the title compound as a white solid.
Step3 vmethyl 3-( 4- f (4-chloro~phenyl)thiolphenyl ~propanoate A solution of ester from step2 in EtOAc (0.2M) containing 10% Pd/C
(0.15 g/ rnmol) was agitated under hydrogen (50 psi, Parr apparatus) for 3h.
The mixture was filtered over Celite and the solvent evaporated to afford the title compound.
Step4: 3-~4-f(4-chlorophen 1)~lphenyllprot~anoic acid A solution of ester from step3 and LiOH (2N, 3 eq) in MeOH (0.2M) was stirred at reflux for 2 h, cooled to rt and acidified to pH 3 with HCl 10%. The mixture was extracted with ether and the solvent evaporated. The residue was purified by stirring vigorously in hexane followed by filtration to give the title compound as a white solid.
Steps: 3-14-f(4-chlorophenyl)thiolphenyl~propanoyl chloride To a solution of acid from step 4 in CH2Cl2 (0.2M) was added oxalyl chloride (1.2 eq) and one drop of DMF. The mixture was stirred at rt for 3h and the solvent evaporated. The crude acid chloride was used as such in the next step.
Step6: 1 a11~4 amino-3-~4-f(4-chlorophenyl)thiolbenzyllguinolin-2(1H)-one Following the procedures described in General Method B, using acid chloride from previous steps and replacing methyl iodide by allyl bromide in step 2 of General Method B, the title compound was isolated as white foam after purification by flash chromatography (hexane-ethyl acetate, 8:2).
1H NMR (400 MHz, acetone-d(): b 7.95 (dd, 1H), 7.52 (dt, 1H), 7.39 (m, 3H), 7.30 (m, 4H), 7.20 (m, 3H), 5.98-5.92 (m, 1H), 5.81 (s, 2H), 5.12-5.0 (m, 2H), 4.97 (m, 2H), 4.07 (s, 2H).

OH
\~ I \
\ CI
O
F
3-[(3'-chloro-4'-fluoro-1,1'-biphenyl-4-yl)methyl]-4-hydroxy-1-methylquinolin-2(lI~-Following the procedures described in General Method A and using 4-[(3-chloro-4-fluorophenyl)]benzaldehyde, stirring vigorously the residue in acetone followed by filtration, the title compound was isolated as white powder.

1-allyl-3-[(3'-chloro-4'-fluoro-1,1'-biphenyl-4-yl)methyl]-4-hydroxyquinolin-2( lI~-Following the procedures described in Example 110, the title compound was isolated as white powder after purification by flash chromatography (hexane-ethyl acetate, 8:2) and stirring vigorously the residue in ether followed by filtration.
1H NMR (400 MHz, acetone-d(): ~ 10.6 (s, OH), 8.04 (d, 1H), 7.79 (dd, 1H), 7.61 (m, 1H), 7.54-7.31 (m, 7H), 7.23 (t, 1H), 5.88 (m, 1H), 5.09 (d, 1H), 4.92 (d, 1H), 4.87 (s, 2H), 4.02 (s, 2H).

I/
CI
/ F
4-amino-3-[(3'-chloro-4'-fluoro-1,1'-biphenyl-4-yl)methyl]-1-methylquinolin-2(1I~-one Following the procedures described in Example 114, the title compound was isolated as white powder after purification by flash chromatography (hexane-ethyl acetate, 8:2) and stirring vigorously the residue in ether followed by filtration.

1H NMR (300 MHz, CDC13): 8 7.58-7.49 (m, 3H), 7.41-7.24 (m, 6H), 7.21-7.11 (m, 2H), 4.45 (s, NH2), 4.11 (s, 2H), 3.74 (s, 3H).

OCFzH
\ CI
\ I \ I /
/ F
3-[(3'-chloro-4'-fluoro-1,1'-biphenyl-4-yl)methyl]-4-(difluoromethoxy)-1-methylguinolin 2(1I~-one A solution of example 145, Cs2C03 (2 eq) in DMF (0.2M) was heated at 100°C (open flask) then methyl chlorodifluoroacetate (2 eq) was added and the mixture stirred at 90-110°C for 3h. After cooling to rt, the mixture was diluted with water, extracted with ethyl acetate and the solvent evaporated. The residue was purified by crystallisation in hexane\ether to give the title compound as a white powder.
1H NMR (400 MHz, acetone-d6): 8 7.89 (d, 1H), 7.76-7.68 (m, 2H), 7.65-7.52 (m, 4H), 7.48-7.33 (m, 4H), 7.05 (t, 1H), 4.15 (s, 2H), 3.75 (s, 3H).

OH
\ ~ \ ~ ~ \ ~ CI
O S
N
O ~O
3 ~4 f(4 chlorophenyl)sulfonXllbenzyl~-4-hydroxy-1-methylauinolin-2(1H)-one Steel: 4-f (4-chlorophe~l)sulfonyllbenzaldehyde A solution of 4-[(4-chlorophenyl)thio]benzaldehyde from example 114, steel and mCPBA (2.2 eq) in CH2C12 was stirred at rt for 1h then Ca(OH)2 (2.2 eq) was added. The mixture was stirred 30 min, filtered and the solvent evaporated.
The residue was purified by stirring vigorously in hexane-ether followed by filtration to give the title compound as a white solid.
Step2: 3 ~4 ((4 chloro~hen~l)sulfonyllbenzyl~-4-hydroxy-1-methylguinolin-2(1I~-one Following the procedures described in General Method A and using aldehyde from step114, the title compound was isolated as white powder after purification by stirring vigorously in ethyl acetate-chloroform-ether followed by filtration.
1H NMR (400 MHz, DMSO-d6): 8 10.6 (s, 1H), x.02 (d, 1H), 7.90 (d, 2H), 7.82 (d, 2H), 7.65 (d, 2H), 7.58 (dt, 1H), 7.44 (m, 3H), 7.25 (t, 1H), 4.03 (s, 2H), 3.54 (s, 3H).
ASSAYS FOR DETERMINING BIOLOGICAL ACTIVITY
The compound of Formula A can be tested using the following assays to determine their prostanoid antagonist or agonist activity in vitro and in vivo and their selectivity. The prostaglandin receptor activities demonstrated are DP, EP1, EP2, EP3, EP4, FP, IP and TP.
Stable expression of prostanoid receptors in the human embryonic kidney (HEK) 293(ebna) cell line Prostanoid receptor cDNAs corresponding to full length coding sequences are subcloned into the appropriate sites of mammalian expression vectors and transfected into HEK 293(ebna) cells. HEK 293(ebna) cells expressing the individual cDNAs are grown under selection and individual colonies are isolated after 2-3 weeks of growth using the cloning ring method and subsequently expanded into clonal cell lines.
-4~-Prostanoid receptor binding assay HEK 293(ebna) cells are maintained in culture, harvested and membranes are prepared by differential centrifugation, following lysis of the cells in the presence of protease inhibitors, for use in receptor binding assays.
Prostanoid receptor binding assays are performed in 10 mM MES/KOH (pH 6.0) (EPs, FP and TP) or 10 mM HEPES/KOH (pH 7.4) (DP and IP), containing 1 mM EDTA, 10 mM
divalent ration and the appropriate radioligand. The reaction is initiated by addition of membrane protein. Ligands are added in dimethylsulfoxide which is kept constant at 1 % (v/v) in all incubations. Non-specific binding is determined in the presence of 1 ,uM of the corresponding non-radioactive prostanoid. Incubations are conducted for 60 min at room temperature or 30 °C and terminated by rapid filtration.
Specific binding is calculated by subtracting non specific binding from total binding.
The residual specific binding at each ligand concentration is calculated and expressed as a function of ligand concentration in order to construct sigmoidal concentration-response curves for determination of ligand affinity.
Prostanoid receptor monist and antagonist assays, Whole cell second messenger assays measuring stimulation (EP2, EP4, DP and IP in HEK 293(ebna) cells) or inhibition (EP3 in human erythroleukemia (HEL) cells) of intracellular cAMP accumulation or mobilization of intracellular calcium (EP1, FP and TP in HEK 293(ebna) cells stably transfected with apo-aequorin) are performed to determine whether receptor ligands are agonists or antagonists. For CAMP assays, cells are harvested and resuspended in HBSS
containing 25 mlVl HEPES, pH 7.4. Incubations contain 100 ~.M RO-20174 (phosphodiesterase type IV inhibitor, available from Biomol) and, in the case of the EP3 inhibition assay only, 15 ,uM forskolin to stimulate cAMP production.
Samples are incubated at 37°C for 10 min, the reaction is terminated and cAMP
levels are then measured. For calcium mobilization assays, cells are charged with the co-factors reduced glutathione and coelenterazine, harvested and resuspended in Ham's FI2 medium. Calcium mobilization is measured by monitoring luminescence provoked by calcium binding to the intracellular photoprotein aequorin. Ligands are added in dimethylsulfoxide which is kept constant at 1 % (v/v) in all incubations. For agonists, second messenger responses are expressed as a function of ligand concentration and both EC50 values and the maximum response as compared to a prostanoid standard are calculated. For antagonists, the ability of a ligand to inhibit an agonist response is determined by Schild analysis and both KB and slope values are calculated.
Rat Paw Edema Assay The method is the same as described in Chan et al (J. Pharmacol. Exp.
Ther. 274: 1531-1537, 1995).
LPS-Induced Pyrexia in Conscious Rats The method is the same as described in Chan et al (J. Pharmacol. Exp.
Ther. 274: 1531-1537, 1995).
LPS-Induced Pyrexia in Conscious Squirrel Monkeys The method is the same as described in Chan et al (Eur. J. Pharmacol.
327: 221- 225, 1997).
Acute Inflammator~Hyperalgesia Induced by Carrageenan in Rats The method is the same as described in Boyce et al (Neuropharmacology 33: 1609-1611, 1994).
Ad~uvant-Induced Arthritis in Rats Female Lewis rats (body weight 146-170 g) are weighed, ear marked, and assigned to groups (a negative control group in which arthritis was not induced, a vehicle control group, a positive control group administered indomethacin at a total daily dose of 1 mg/lcg and four groups administered with a test compound at total daily doses of 0.10-3.0 mg/kg) such that the body weights were equivalent within each group. Six groups of 10 rats each were injected into a hind paw with 0.5 mg of Mycohacteriuoa butyricum in 0.1 mL of light mineral oil (adjuvant), and a negative control group of 10 rats was not injected with adjuvant. Body weights, contralateral paw volumes (determined by mercury displacement plethysmography) and lateral , radiographs (obtained under Ketamine and Xylazine anesthesia) were determined before (day -1) and 21 days following adjuvant injection, and primary paw volumes were determined before (day -1) and on days 4 and 21 following adjuvant injection.
The rats were anesthetized with an intramuscular injection of 0.03 - 0.1 mL of a combination of Ketamine (~7 mg/lcg) and Xylazine (13 mg/kg) for radiographs and injection of adjuvant. The radiographs were made of both hind paws on day 0 and day 21 using the Faxitron (45 kVp, 30 seconds) and Kodak X-GMAT TL film, and were developed in an automatic processor. Radiographs were evaluated for changes in the soft and hard tissues by an investigator who was blinded to experimental treatment.
The following radiographic changes were graded numerically according to severity:
increased soft issue volume (0-4), narrowing or widening of joint spaces (0-5) subchondral erosion (0-3), periosteal reaction (0-4), osteolysis (0-4) subluxation (0-3), and degenerative joint changes (0-3). Specific criteria were used to establish the numerical grade of severity for each radiographic change. The maximum possible score per foot was 26. A test compound at total daily doses of 0.1, 0.3, 1, and 3 mg/kg/day, indomethacin at a total daily dose of 1 mg/lcg/day, or vehicle (0.5%
methocel in sterile water) were administered per os b.i.d. beginning post injection of adjuvant and continuing for 21 days. The compounds are prepared weekly, refrigerated in the dark until used, and vortex mixed immediately prior to administration.

Claims (24)

WHAT IS CLAIMED IS:
1. A method for treating a prostaglandin E mediated disease or condition comprising administering to a mammalian patient in need of such treatment a compound of Formula A:

or a pharmaceutically acceptable salt, hydrate, ester or tautomer thereof, wherein:
R1 is selected from the group consisting of:

(1) hydrogen, (2) halo, (3) hydroxy, (4) C1-6alkyl, (5) C1-6alkenyl, (6) C1-6alkoxy, (7) C1-6alkyl-S(O)m-, wherein m is 0, 1, 2 or 3 (8) C1-6alkyl-C(O)-(7) C1-6alkoxy-C(O)-(9) C1-6alkyl-C(O)-O-(10) aryl, (11) aralkyl, (12) aryloxy, (13) aralkoxy, (14) arylthio, (15) aroyl, (16) aroyloxy, and (17) N(R8)2, wherein the alkyl , alkenyl and aryl portions of items (4)-(16) above are optionally substituted from one up to the maximum number of substituable positions with a member independently selected from the group consisting of: halo, heterocycle, 6alkoxy, C1-6allkyl-S(O)k-, wherein k is 0, 1 or 2, C1-6allkyl-C(O)-, C1-6allcoxy-C(O), C1-6allkyl-C(O)-O, carboxy, hydroxy and aralkcoxy, the alkyl portions of said C1-6alkoxy, C1-6alkyl-S(O)k-, C1-6alkyl-C(O)-, C1-6alkoxy-C(O) and C1-6allkyl-C(O)-O groups optionally substituted with 1-3 substituents independently selected from: halo and hydroxy, said aryl portions of items (10)-(16) above further optionally substituted from one up to the maximum number of substituable positions with C1-6alkyl, optionally substituted with 1-3 substituents independently selected from the group consisting of:
halo and hydroxy;
R2 is selected from the group consisting of:
(1) benzyl, optionally substituted with 1-3 substituents independently selected from the group consisting of:
(a) halo, (b) aryl, (c) aryloxy, (d) aryl-S(O)k-, wherein k is 0, 1 or 2, (e) heterocycle, (f) aralkyl, (g) aroyl, (h) aroyloxy, (i) C1-6alkyl, (j) C1-6alkenyl, (k) C1-6alkoxy, (1) C1-6alkyl-S(O)k-, wherein k is 0, 1 or 2, (m) C1-6allkyl-C(O)-, (n) C1-6allcoxy-C(O), (o) C1-6alkyl-C(O)-O-, (p) carboxy, (q) hydroxy, (r) N(R8)2, (s) SO2R8, and (t) SO2N(R8)2 wherein the alkyl, alkenyl, aryl and heterocycle portions of items (b)-(o) above are optionally substituted from one up to the maximum number of substituable positions with a member independently selected from the group consisting of: halo, heterocycle, C1-6alkoxy, C1-6alkyl-S(O)k-, wherein k is 0, 1 or 2, C1-6alkyl-C(O)-, C1-6alkoxy-C(O)-, C1-6alkyl-C(O)-O-, aralkoxy, carboxy and hydroxy, the alkyl portions of said C1-6alkoxy, C1-6alkyl-S(O)k-, C1-6alkyl-C(O)-, C1-6alkoxy-C(O) and C1-6alkyl-C(O)-O groups optionally substituted with 1-3 substituents independently selected from halo and hydroxy;

said aryl and heterocycle portions of items (b)-(h) above further optionally substituted from one up to the maximum number of substituable positions with C1-6alkyl optionally substituted with 1-3 substituents independently selected from the group consisting of: halo and hydroxy;

(2) C1-7alkyl or C1-6alkenyl, each optionally substituted with 1-3 groups independently selected from the group consisting of: halo, hydroxy, C3-6cycloalkyl, aryl and heterocycle, said aryl and heterocycle optionally substituted with 1-3 substituents independently selected from:
(a) halo, (b) hydroxy, (c) aryl, optionally substituted with 1-3 halo groups, and (d) C1-6alkyl, optionally substituted independently with 1-3 halo or hydroxy groups, except that when R2 is methyl monosubstituted with aryl as phenyl then R2 is defined as in (1) above, and (3) aroyl, optionally substituted with aryloxy or arylthio, said aryloxy or arylthio optionally substituted with 1-3 halo groups;

R3 is selected from the group consisting of:
(1) C1-6alkyl, C2-6alkenyl or C3-6alkynyl, each optionally substituted with 1-3 halo groups, (2) aryl, optionally substituted with 1-3 halo groups, and (3) aralkyl, optionally substituted with a substituent independently selected from the group consisting of: C1-6alkylsulfonyl and halo, R4, R5, R6 and R7 are each independently selected from the group consisting of:
(1) hydrogen, (2) halo, and (3) C1-6alkyl, optionally substituted with 1-3halo groups, or R3 and R4 may be joined together with the atoms to which they are attached to form a monocyclic ring as shown in Formula A' wherein R14 is selected from the groups consisting of: halo, C1-6alkyl or aryl, wherein C1-6alkyl and aryl are optionally substituted with 1-3 halo groups;
and R8 is selected from the group consisting of H, C1-6alkyl, C1-6alkenyl and C1-6alkyl-C(O)-, the alkyl and alkenyl portions of which are optionally substituted with 1-3 halo groups, in an amount which is effective for treating the prostaglandin E mediated disease.
2. ~The method according to Claim 1 wherein the prostaglandin E
mediated disease or condition is selected from the group consisting of:
(1) ~pain, fever or inflammation associated with rheumatic fever, influenza or other viral infections, common cold, low back and neck pain, skeletal pain, post-parfum pain, dysmenomhea, headache, migraine, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns including radiation and corrosive chemical injuries, sunburns, pain following surgical and dental procedures as well as immune and autoimmune diseases;
(2) ~cellular neoplastic transformations or metastic tumor growth;
(3) ~diabetic retinopathy and tumor angiogenesis;
(4) ~prostanoid-induced smooth muscle contraction associated with dysmenorrhea, premature labor, asthma or eosinophil related disorders;
(5) ~Alzheimer's disease;
(6)~glaucoma;
(7)~bone loss;
(8)~osteoporosis;
(9) ~promotion of bone formation;
(10) ~Paget's disease;
(11) ~cytoprotection in peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or other gastrointestinal lesions;
(12) ~GI bleeding and patients undergoing chemotherapy;
(13) ~coagulation disorders selected from hypoprothrombinemia, haemophilia and other bleeding problems;
(14) ~kidney disease;
(15)~thrombosis;
(16) ~occlusive vascular disease;~
(17)~presurgery;
(18)~anti-coagulation;
(19)~neuropathic pain; and (20) ~urinary incontinence.
3. The method according to Claim 2 wherein the prostaglandin E
mediated disease or condition is selected from the group consisting of: pain, fever or inflammation associated with rheumatic fever, influenza or other viral infections, common cold, low back and neck pain, skeletal pain, post-partum pain, dysmenorrhea, headache, migraine, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns including radiation and corrosive chemical injuries, sunburns, pain following surgical and dental procedures as well as immune and autoimmune diseases.
4. The method according to Claim 3 wherein the prostaglandin E
mediated disease or condition is pain, fever or inflammation associated with dysmenorrhea.
5. The method according to Claim 1, wherein the compound of Formula A is co-administered with other agents or ingredients.
6. The method according to Claim 5 wherein the compound of Formula A is co-administered with another agent or ingredient selected from the group consisting of:
(1) an analgesic selected from acetaminophen, phenacetin, aspirin, a narcotic;
(2) a cyclooxygenase-2 selective nonsteroidal anti-inflammatory drug or a conventional nonsteroidal anti-inflammatory drug;
(3) caffeine;
(4) an H2-antagonist;
(5) aluminum or magnesium hydroxide;
(6) simethicone;
(7) a decongestant selected from phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine;
(8) an antiitussive selected from codeine, hydrocodone, caramiphen, carbetapentane and dextramethorphan;
(9) another prostaglandin ligand selected from misoprostol, enprostil, rioprostil, ornoprostol and rosaprostol; a diuretic; and (10) a sedating or non-sedating antihistamine.
7. The method according to Claim 6 wherein the compound of Formula A is co-administered with a cyclooxygenase-2 selective nonsteroidal anti-inflammatory drug or a conventional nonsteroidal anti-inflammatory drug.
8. A method according to Claim 7 wherein the compound of Formula A is co-administered with a conventional nonsteroidal anti-inflammatory drug selected from the group consisting of: aspirin, ibuprofen, naproxen, and ketoprofen.
9. A method according to Claim 7 wherein the compound of Formula A is co-administered with a cyclooxygenase-2 selective nonsteroidal anti-inflammatory drug selected from rofecoxib, etoricoxib, valdecoxib, parecoxib and celecoxib.
10. The method according to Claim 1 wherein:
R2 is benzyl, optionally substituted with 1-3 substituents independently selected from the group consisting of:
(a) halo, (b) aryl, (c) aryloxy, (d) aryl-S(O)k, wherein k is 0, 1 or 2, (e) heterocycle, (f) aralkyl, (g) aroyl, (h) aroyloxy, (i) C1-6alkyl, (j) C1-6alkenyl, (k) C1-6alkoxy, (l) C1-6alkyl-S(O)k, wherein k is 0, 1 or 2, (m) C1-6alkyl-C(O)-, (n) C1-6alkoxy-C(O), (o) C1-6alkyl-C(O)-O-, (p) carboxy, (q) hydroxy, and (r) N(R8)2, wherein the alkyl , alkenyl, aryl and heterocycle portions of items (b)-(o) above are optionally substituted from one up to the maximum number of substituable positions with a member independently selected from the group consisting of: halo, heterocycle, C1-6alkoxy, C1-6alkyl-S(O)k -, C1-6alkyl-C(O)-, C1-6alkoxy-C(O)-, C1-6alkyl-C(O)-O-, aralkoxy, carboxy and hydroxy, the alkyl portions of said C1-6alkoxy, C1-6alkyl-S(O)k-, C1-6alkyl-C(O)-, C1-6alkoxy-C(O) and C1-6alkyl-C(O)-O groups optionally substituted with 1-3 substituents independently selected from halo and hydroxy;
said aryl and heterocycle portions of items (b)-(h) above further optionally substituted from one up to the maximum number of substituable positions with C1-6alkyl optionally substituted with 1-3 substituents independently selected from the group consisting of: halo and hydroxy.
11. The method according to Claim 10 wherein R2 is mono-, di or tri substituted benzyl, wherein the substituents are independently selected from the group consisting of:
(a) aryl, (b) aryloxy, (c) aryl-S(O)k -, wherein k is 0, 1 or 2, (d) heterocycle, (e) aralkyl, (f) aroyl, and (g) aroyloxy, the aryl and heterocycle portions of items (a)-(g) above are optionally substituted from one up to the maximum number of substituable positions with a member independently selected from the group consisting of: halo, C1-6alkyl, C1-6alkoxy, C1-6alkyl-S(O)k -, C1-6alkyl-C(O)-, C1-6alkoxy-C(O)-, C1-6alkyl-C(O)-O-, aralkoxy, carboxy and hydroxy, the alkyl portions of said C1-6alkoxy, C1-6alkyl-S(O)k-, C1-6alkyl-C(O)-, C1-6alkoxy-C(O) and C1-6alkyl-C(O)-O groups optionally substituted with 1-3 substituents independently selected from halo and hydroxy.
12. The method according to Claim 11 wherein R2 is mono-, di- or tri-substituted benzyl, with the proviso that at least one of the substituents is attached to the benzyl group at the 4-position.
13. The method according to Claim 1 wherein R1 is methoxy, difluoromethoxy, hydroxy or amino.
14. The method according to Claim 1 wherein R3 is benzyl, phenyl, ethyl, propyl, methyl or allyl.
15. The method according to Claim 1 wherein the compound is selected from the following table:

16. The method according to Claim 1 wherein the compound is selected from the following table:

R4=H; R5=H, R6=H; R7=H
17. The method according to Claim 1 wherein the compound is selected from the following table:

18. A compound of Formula B
or a pharmaceutically acceptable salt, hydrate, ester or tautomer thereof, wherein:
X is selected from a bond, O or S(O)k, wherein k is 0, 1 or 2, R1 is selected from the group consisting of:
(1) hydrogen, (2) halo, (3) hydroxy, (4) C1-6alkyl, (5) C1-6alkenyl, (6) C1-6alkoxy, (7) C1-6alkyl-S(O)m-, wherein m is 0, 1, 2 or 3 (8) C1-6alkyl-C(O)-(7) C1-6alkoxy-C(O)-(9) C1-6alkyl-C(O)-O-(10) aryl, (11) aralkyl, (12) aryloxy, (13) aralkoxy, (14) arylthio, (15) aroyl, (16) aroyloxy and (17) N(R8)2, wherein the alkyl , alkenyl and aryl portions of items (4)-(16) above are optionally substituted from one up to the maximum number of substituable positions with a member independently selected from the group consisting of: halo, heterocycle, 6alkoxy, C1-6alkyl-S(O)k-, C1-6alkyl-C(O)-, C1-6alkoxy-C(O), C1-6alkyl-C(O)-O, carboxy, hydroxy and aralkoxy, the alkyl portions of said C1-6alkoxy, C1-6alkyl-S(O)k-, C1-6alkyl-C(O)-, C1-6alkoxy-C(O) and C1-6alkyl-C(O)-O groups optionally substituted with 1-3 substituents independently selected from: halo and hydroxy, said aryl portions of items (10)-(16) above further optionally substituted from one up to the maximum number of substituable positions with C1-6alkyl, optionally substituted with 1-3 substituents independently selected from the group consisting of:
halo and hydroxy;
R3 is selected from the group consisting of:
(1) C1-6alkyl, C2-6alkenyl or C3-6alkynyl, each optionally substituted with 1-3 halo groups.

(2) aryl, optionally substituted with 1-3 halo groups, (3) aralkyl, optionally substituted with a substituent independently selected from the group consisting of: C1-6alkylsulfonyl and halo, R4, R5, R6 and R7 are each independently selected from the group consisting of:
(1) hydrogen, (2) halo, and (3) C1-6alkyl, optionally substituted with 1-3 halo groups, or R3 and R4 may be joined together with the atoms to which they are attached to form a monocyclic ring as shown in Formula B':
wherein R14 is selected from the groups consisting of: halo, C1-6alkyl, aryl or heterocycle, wherein C1-6alkyl, heterocycle and aryl are optionally substituted with 1-3 substituents independently selected from halo, C1-3alkyl, carboxy, SO2C1-3alkyl or SO2N(C1-3alkyl)2 , said C1-3alkyl is optionally substituted with a hydroxy group, and R8 is selected from the group consisting of H, C1-6alkyl, C1-6alkenyl, C1-6alkyl-C(O)- and aryl, the aryl, alkyl and alkenyl portions are optionally substituted with 1-3 halo groups, R9 and R10 are independently selected from the group consisting of:
(1) halo, (2) C1-6alkyl, (3) C1-6alkenyl, (4) C1-6alkoxy, (5) C1-6alkyl-S(O)k-, wherein k is 0, 1 or 2, (6) C1-6alkyl-C(O)-, (7) C1-6alkoxy-C(O), (8) C1-6alkyl-C(O)-O-, (9) carboxy, (10) hydroxy, and (11) N(R8)2, wherein the alkyl and alkenyl portions of items (2)-(8) above are optionally substituted from one up to the maximum number of substituable positions with a member independently selected from the group consisting of: halo, heterocycle, 6alkoxy, C1-6alkyl-S(O)k-, C1-6alkyl-C(O)-, C1-6alkoxy-C(O)-, C1-6alkyl-C(O)-O-, aralkoxy, carboxy and hydroxy, the alkyl portions of said C1-6alkoxy, C1-6alkyl-S(O)k-, C1-6alkyl-C(O)-, C1-6alkoxy-C(O) and C1-6alkyl-C(O)-O groups optionally substituted with 1-3 substituents independently selected from halo and hydroxy.
19. The compound according to Claim 18 wherein:
X is selected from a bond, O or S(O)k, wherein k is 0, 1 or 2, R1 is selected from the group consisting of:
(1) halo, (2) hydroxy, (3) C1-6alkyl, (4) C1-6alkoxy, and (5) N(R8)2, wherein R8 is H or C1-4alkyl, wherein the alkyl portions of items (3)-(4) above are optionally substituted with 1-3 halo groups, R3 is C1-6alkyl or C2-4alkenyl, each optionally substituted with 1-3 halo groups.
R4, R5, R6, R7 and R9 are each H, and R10 is H or halo.
20. The compound according to Claim 19 selected from the group consisting of:
(1) 3-{4-[(4-chlorophenyl)thio]benzyl}-4-hydroxy-1-methylquinolin-2(1H)-one;
(2) 1-allyl-3-{4-[(4-chlorophenyl)thio]benzyl}-4-hydroxyquinolin-2(1H)-one;
(3) 1-allyl-4-amino-3-{4-[(4-chlorophenyl)thio]benzyl}quinolin-2(1H)-one;
(4) 3-[(3'-chloro-4'-fluoro-1,1'-biphenyl-4-yl)methyl]-4-hydroxy-1-methylquinolin-2(1H)-one;
(5) 1-allyl-3-[(3'-chloro-4'-fluoro-1,1'-biphenyl-4-yl)methyl]-4-hydroxyquinolin-2(1H)-one;
(6) 4-amino-3-[(3'-chloro-4'-fluoro-1,1'-biphenyl-4-yl)methyl]-1-methylquinolin-2(1H)-one;
(7) 3-[(3'-chloro-4'-fluoro-1,1'-biphenyl-4-yl)methyl]-4-(difluoromethoxy)-1-methylquinolin-2(1H)-one; and (8) 3-{4-[(4-chlorophenyl)sulfonyl]benzyl}-4-hydroxy-1-methylquinolin-2(1H)-one.
21. Use of a compound of Formula A, as defined in any one of Claims 1 to 17, or a pharmaceutically acceptable salt, hydrate, ester or tantomer thereof, in the manufacture of a medicament for treating a prostaglandin E
mediated disease or condition.
22. Use of a compound of Formula B, as defined in Claims 18, 19 or 20, or a pharmaceutically acceptable salt, hydrate, ester or tantomer thereof, in the manufacture of a medicament for treating a prostaglandin E mediated disease or condition.
23. A pharmaceutical composition for treating a prostaglandin E
mediated disease or condition comprising an acceptable, effective amount of a compound of Formula A as defined in any one of Claims 1 to 17, or a pharmaceutically acceptable salt, hydrate, ester or tantomer thereof, in the manufacture of a medicament for treating a prostaglandin E mediated disease or condition, in association with a pharmaceutically acceptable carrier.
24. A pharmaceutical composition for treating a prostaglandin E
mediated disease or condition comprising an acceptable, effective amount of a compound of Formula B, as defined in Claims 18, 19 or 20, or a pharmaceutically acceptable salt, hydrate, ester or tantomer thereof, in the manufacture of a medicament for treating a prostaglandin E mediated disease or condition in association with a pharmaceutically acceptable carrier.
CA002469048A 2001-12-14 2002-12-11 Quinolinones as prostaglandin receptor ligands Abandoned CA2469048A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34043901P 2001-12-14 2001-12-14
US60/340,439 2001-12-14
PCT/CA2002/001914 WO2003051878A1 (en) 2001-12-14 2002-12-11 Quinolinones as prostaglandin receptor ligands

Publications (1)

Publication Number Publication Date
CA2469048A1 true CA2469048A1 (en) 2003-06-26

Family

ID=23333355

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002469048A Abandoned CA2469048A1 (en) 2001-12-14 2002-12-11 Quinolinones as prostaglandin receptor ligands

Country Status (9)

Country Link
US (1) US7348433B2 (en)
EP (1) EP1458718B1 (en)
JP (1) JP2005520797A (en)
AT (1) ATE343577T1 (en)
AU (1) AU2002350315B2 (en)
CA (1) CA2469048A1 (en)
DE (1) DE60215699T2 (en)
ES (1) ES2274111T3 (en)
WO (1) WO2003051878A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122403A1 (en) * 2005-05-19 2006-11-23 Merck Frosst Canada Ltd. Quinoline derivatives as ep4 antagonists

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007015833A (en) 2005-07-13 2008-04-09 Sca Hygiene Prod Ab Absorbent article having improved fit.
CA2614735A1 (en) 2005-07-13 2007-01-18 Sca Hygiene Products Ab Absorbent article having improved fit
GB2439719A (en) 2006-07-05 2008-01-09 Sca Hygiene Prod Ab Absorbent article with differing core density regions
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
EP2201374B1 (en) * 2007-08-30 2015-10-07 Trustees Of Tufts College Methods for determining the concentration of an analyte in solution.
KR101523126B1 (en) 2008-07-31 2015-05-26 세노믹스, 인코포레이티드 Processes and intermediates for making sweet taste enhancers
JP2015178457A (en) * 2012-07-25 2015-10-08 杏林製薬株式会社 Pyrazolopyridine derivative and pharmacologically permissible salt of the same
CA2879554A1 (en) 2012-08-06 2014-02-13 Senomyx, Inc. Substituted 4-amino-1h-2,1,3-benzothiadiazine 2,2-dioxide compounds and their use as sweet flavor modifiers
JO3155B1 (en) 2013-02-19 2017-09-20 Senomyx Inc Sweet flavor modifier
CN103319403B (en) * 2013-05-10 2016-03-30 重庆理工大学 Own quinoline ketone of a kind of neonate tumour blood vessel inhibitor and its production and use
JP6539274B2 (en) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド Extruded immediate release abuse deterrent pills
KR101731102B1 (en) 2013-10-01 2017-04-27 광주과학기술원 Novel Quinolinone Derivatives and Uses Thereof
CN103664777A (en) * 2013-10-09 2014-03-26 重庆理工大学 2-undecyl-3-methyl-hydroxyl-quinoline compound as well as preparation method, pharmaceutical composition and use thereof
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CN103755697B (en) * 2014-01-14 2015-08-05 湖南大学 3-[[2-(2-benzyl imino-) thiazole-5-base] methyl] quinoline-2 (1H)-one and preparation and application thereof
CN103739599B (en) * 2014-01-15 2015-10-07 湖南大学 3-[[2-(2-benzyl hydrazono-) thiazole-5-base] methyl] quinoline-2 (1H)-one and preparation and application thereof
JP6371463B2 (en) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド Immediate release abuse deterrent liquid filler form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN104628717B (en) * 2015-03-16 2017-02-15 湖南大学 3-[5-(1,2,4-triazole-1-yl) thiazole-2-yl] benzoxazine and application thereof
CN105753857B (en) * 2016-02-16 2018-05-22 湖南大学 The medical usage of benzyl imino thiazole methylquinoline ketone derivatives
CN105541827B (en) * 2016-02-16 2018-01-19 湖南大学 Benzyl hydrazono- benzothiazolylmethyl qualone derivative and its application as anticarcinogen
CN105777739B (en) * 2016-02-23 2018-05-08 湖南大学 Naphthylamino thiazole methyl qualone derivative and its medical usage
CN112703193A (en) 2018-08-07 2021-04-23 弗门尼舍公司 5-substituted 4-amino-1H-benzo [ c ] [1,2,6] thiadiazine 2, 2-dioxides and formulations and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8448491A (en) 1990-09-07 1992-03-30 Schering Corporation Antiviral compounds and antihypertensive compounds
CA2091172C (en) 1990-09-07 1997-05-20 Adriano Afonso Antiviral compounds and antihypertensive compounds
DE19613591A1 (en) * 1996-04-04 1997-10-09 Hoechst Ag Substituted quinoline derivatives, process for their preparation and their use
US6265421B1 (en) 1997-06-25 2001-07-24 Orion Corporation Phospholamban inhibitors and a method for increasing coronary flow
WO2000034244A1 (en) 1998-12-04 2000-06-15 Bristol-Myers Squibb Company 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122403A1 (en) * 2005-05-19 2006-11-23 Merck Frosst Canada Ltd. Quinoline derivatives as ep4 antagonists
US8013159B2 (en) 2005-05-19 2011-09-06 Merck Canada Inc. Quinoline derivatives as EP4 antagonists

Also Published As

Publication number Publication date
EP1458718B1 (en) 2006-10-25
US7348433B2 (en) 2008-03-25
AU2002350315A1 (en) 2003-06-30
DE60215699T2 (en) 2007-08-30
JP2005520797A (en) 2005-07-14
DE60215699D1 (en) 2006-12-07
ATE343577T1 (en) 2006-11-15
WO2003051878A1 (en) 2003-06-26
AU2002350315B2 (en) 2008-05-22
ES2274111T3 (en) 2007-05-16
US20050222194A1 (en) 2005-10-06
EP1458718A1 (en) 2004-09-22

Similar Documents

Publication Publication Date Title
CA2469048A1 (en) Quinolinones as prostaglandin receptor ligands
US6627656B2 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore
AU2006261845B2 (en) Imidazole based LXR modulators
KR100228949B1 (en) Bicyclic tetrahydro pyrazolopyridines
CA2700824A1 (en) Heterocyclic compounds as crth2 receptor antagonists
EP1216238B1 (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
AU2005331482B2 (en) Dihydropyridine derivatives
AU772841B2 (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
AU752820B2 (en) Biphenylene lactams as prostaglandin receptor ligands
WO2010040989A1 (en) Quinolin-2-one compounds
AU2708699A (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
RU2372337C2 (en) Dihydropyridine derivatives
KR20080011402A (en) Dihydropyridine derivatives

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued